PANA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PANA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Panacea Acquisition II's Tax Expense for the three months ended in Dec. 2022 was $0.00 Mil. Panacea Acquisition II's Pre-Tax Income for the three months ended in Dec. 2022 was $1.23 Mil. Therefore, Panacea Acquisition II's Tax Rate % for the quarter that ended in Dec. 2022 was 0.00%.
The historical data trend for Panacea Acquisition II's Tax Rate % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Acquisition II Annual Data | |||||
Trend | Dec21 | Dec22 | |||
Tax Rate % | - | - |
Panacea Acquisition II Quarterly Data | ||||||||
Jan21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Tax Rate % | Get a 7-Day Free Trial | - | - | - | - | - |
Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.
Panacea Acquisition II's Tax Rate % for the fiscal year that ended in Dec. 2022 is calculated as
Tax Rate % | = | Tax Expense (A: Dec. 2022 ) | / | Pre-Tax Income (A: Dec. 2022 ) |
= | 0 | / | 1.428 | |
= | 0.00 % |
Panacea Acquisition II's Tax Rate % for the quarter that ended in Dec. 2022 is calculated as
Tax Rate % | = | Tax Expense (Q: Dec. 2022 ) | / | Pre-Tax Income (Q: Dec. 2022 ) |
= | 0 | / | 1.234 | |
= | 0.00 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Panacea Acquisition II's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ecor1 Capital Fund Qualified, L.p. | director, 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Ecor1 Capital, Llc | director, 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Oleg Nodelman | director, 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Ecor1 Capital Fund, L.p. | director, 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Ecor1 Venture Opportunity Fund, Lp | director, 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Biotech Opportunity Gp, Llc | director, 10 percent owner | 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558 |
Ecor1 Panacea Holdings Ii, Llc | director, 10 percent owner | 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103 |
Douglas E Williams | director | C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799 |
Douglas E. Giordano | director | C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017 |
Nina S Kjellson | director | C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025 |
Praveen P. Tipirneni | director | C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451 |
Sarah Marriott | director, officer: Secretary | C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103 |
Scott Perlen | officer: Chief Financial Officer | C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103 |
Caroline Stout | officer: Chief Investment Officer | C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103 |
Scott Platshon | officer: Chief Operating Officer | C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103 |
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.